Oral Antiplatelet Therapy After Acute Coronary Syndrome
Authors:
Top Cited Papers
- 20 April 2021
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (15) , 1545-1555
Abstract
Importance Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event rates after ACS. Observations In 2016, the updated guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommended aspirin plus a P2Y12 inhibitor for at least 12 months for patients with ACS. Since these recommendations were published, new randomized clinical trials have studied different regimens and durations of antiplatelet therapy. Recommendations vary according to the risk of bleeding. If bleeding risk is low, prolonged DAPT may be considered, although the optimal duration of prolonged DAPT beyond 1 year is not well established. If bleeding risk is high, shorter duration (ie, 3-6 months) of DAPT may be reasonable. A high risk of bleeding traditionally is defined as a 1-year risk of serious bleeding (either fatal or associated with a ≥3-g/dL drop in hemoglobin) of at least 4% or a risk of an intracranial hemorrhage of at least 1%. Patients at higher risk are 65 years old or older; have low body weight (BMI P = .002) and should avoid prescribing it to patients older than 75 years or who weigh less than 60 kg. The ISAR-REACT-5 trial found that prasugrel reduced rates of death, myocardial infarction, or stroke at 1 year compared with ticagrelor among patients with ACS undergoing percutaneous coronary intervention (9.3% vs 6.9%,P = .006) with no significant difference in bleeding. Recent trials suggested that discontinuing aspirin rather than the P2Y12 inhibitor may be associated with better outcomes. Conclusions and Relevance Dual antiplatelet therapy reduces rates of cardiovascular events in patients with acute coronary syndrome. Specific combinations and duration of dual antiplatelet therapy should be based on patient characteristics—risk of bleeding myocardial ischemia.Keywords
This publication has 63 references indexed in Scilit:
- Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary SyndromesNew England Journal of Medicine, 2013
- Elderly Patients With Acute Coronary Syndromes Managed Without RevascularizationCirculation, 2013
- Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary StentingNew England Journal of Medicine, 2012
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2012
- Vascular Smooth Muscle Cell Proliferation in RestenosisCirculation: Cardiovascular Interventions, 2011
- Clopidogrel pathwayPharmacogenetics and Genomics, 2010
- P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical useEuropean Heart Journal, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983